Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients

Siddika E Karakas, B. Stern, S. Khilnani, P. McLin, S. Baciorowski, K. L C Jen

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

We investigated the effects of ω-3 fish oil (FO) supplementation on lipid metabolism, glycemic control, and blood pressure (BP) in patients with type II diabetes mellitus. In 22 diabetic patients without overt hyperlipidemia, serum triglyceride, total cholesterol, high density lipoprotein (HDL)-cholesterol, HDL2-cholesterol, HDL3-cholesterol, and apolipoprotein A-I (apo A-I) levels did not change during ω-3 FO supplementation for 8 weeks. The mean serum apo B concentration increased significantly [baseline, 2.56 ± 0.11 (± SEM) mmol/L; 4 weeks, 2.82 ± 0.13 mmol/L; 8 weeks, 2.80 ± 0.13 mmol/L; P < 0.01]. The mean plasma postheparin lipoprotein lipase activity increased transiently during the fourth week (baseline, 168 ± 17 U/mL; 4 weeks, 182 ± 18 U/mL; P < 0.05), whereas postheparin hepatic triglyceride lipase activity did not change. Glycemic control worsened transiently during the fourth week, (baseline, 7.7 ± 0.4%; 4 weeks, 8.4 ± 0.3%; P < 0.05). Both systolic and diastolic BP decreased significantly throughout the study (systolic BP: baseline, 142 ± 5 mm Hg; 8 weeks, 128 ± 5 mm Hg; diastolic BP: baseline, 88 ± 4 mm Hg; 8 weeks, 80 ± 3 mm Hg; P < 0.01). These findings suggest that in type II diabetics without overt hyperlipidemia, ω-3 FO supplementation does not improve either the glycemic control or serum lipids, and it is associated with a potentially detrimental rise in serum apo B concentrations. Until more information is available, use of such supplementation should be discouraged.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume67
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Fish Oils
Blood pressure
Lipid Metabolism
HDL Cholesterol
Blood Pressure
Apolipoproteins B
Hyperlipidemias
Lipoprotein Lipase
Serum
Cholesterol
Apolipoprotein A-I
Medical problems
Lipase
HDL2 Lipoprotein
Triglycerides
Lipids
Plasmas
Scanning electron microscopy
Type 2 Diabetes Mellitus
Liver

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients. / Karakas, Siddika E; Stern, B.; Khilnani, S.; McLin, P.; Baciorowski, S.; Jen, K. L C.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 67, No. 1, 1988, p. 1-5.

Research output: Contribution to journalArticle

@article{d51307d9e10e4cb4bc5efff15153f2cb,
title = "Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients",
abstract = "We investigated the effects of ω-3 fish oil (FO) supplementation on lipid metabolism, glycemic control, and blood pressure (BP) in patients with type II diabetes mellitus. In 22 diabetic patients without overt hyperlipidemia, serum triglyceride, total cholesterol, high density lipoprotein (HDL)-cholesterol, HDL2-cholesterol, HDL3-cholesterol, and apolipoprotein A-I (apo A-I) levels did not change during ω-3 FO supplementation for 8 weeks. The mean serum apo B concentration increased significantly [baseline, 2.56 ± 0.11 (± SEM) mmol/L; 4 weeks, 2.82 ± 0.13 mmol/L; 8 weeks, 2.80 ± 0.13 mmol/L; P < 0.01]. The mean plasma postheparin lipoprotein lipase activity increased transiently during the fourth week (baseline, 168 ± 17 U/mL; 4 weeks, 182 ± 18 U/mL; P < 0.05), whereas postheparin hepatic triglyceride lipase activity did not change. Glycemic control worsened transiently during the fourth week, (baseline, 7.7 ± 0.4{\%}; 4 weeks, 8.4 ± 0.3{\%}; P < 0.05). Both systolic and diastolic BP decreased significantly throughout the study (systolic BP: baseline, 142 ± 5 mm Hg; 8 weeks, 128 ± 5 mm Hg; diastolic BP: baseline, 88 ± 4 mm Hg; 8 weeks, 80 ± 3 mm Hg; P < 0.01). These findings suggest that in type II diabetics without overt hyperlipidemia, ω-3 FO supplementation does not improve either the glycemic control or serum lipids, and it is associated with a potentially detrimental rise in serum apo B concentrations. Until more information is available, use of such supplementation should be discouraged.",
author = "Karakas, {Siddika E} and B. Stern and S. Khilnani and P. McLin and S. Baciorowski and Jen, {K. L C}",
year = "1988",
language = "English (US)",
volume = "67",
pages = "1--5",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients

AU - Karakas, Siddika E

AU - Stern, B.

AU - Khilnani, S.

AU - McLin, P.

AU - Baciorowski, S.

AU - Jen, K. L C

PY - 1988

Y1 - 1988

N2 - We investigated the effects of ω-3 fish oil (FO) supplementation on lipid metabolism, glycemic control, and blood pressure (BP) in patients with type II diabetes mellitus. In 22 diabetic patients without overt hyperlipidemia, serum triglyceride, total cholesterol, high density lipoprotein (HDL)-cholesterol, HDL2-cholesterol, HDL3-cholesterol, and apolipoprotein A-I (apo A-I) levels did not change during ω-3 FO supplementation for 8 weeks. The mean serum apo B concentration increased significantly [baseline, 2.56 ± 0.11 (± SEM) mmol/L; 4 weeks, 2.82 ± 0.13 mmol/L; 8 weeks, 2.80 ± 0.13 mmol/L; P < 0.01]. The mean plasma postheparin lipoprotein lipase activity increased transiently during the fourth week (baseline, 168 ± 17 U/mL; 4 weeks, 182 ± 18 U/mL; P < 0.05), whereas postheparin hepatic triglyceride lipase activity did not change. Glycemic control worsened transiently during the fourth week, (baseline, 7.7 ± 0.4%; 4 weeks, 8.4 ± 0.3%; P < 0.05). Both systolic and diastolic BP decreased significantly throughout the study (systolic BP: baseline, 142 ± 5 mm Hg; 8 weeks, 128 ± 5 mm Hg; diastolic BP: baseline, 88 ± 4 mm Hg; 8 weeks, 80 ± 3 mm Hg; P < 0.01). These findings suggest that in type II diabetics without overt hyperlipidemia, ω-3 FO supplementation does not improve either the glycemic control or serum lipids, and it is associated with a potentially detrimental rise in serum apo B concentrations. Until more information is available, use of such supplementation should be discouraged.

AB - We investigated the effects of ω-3 fish oil (FO) supplementation on lipid metabolism, glycemic control, and blood pressure (BP) in patients with type II diabetes mellitus. In 22 diabetic patients without overt hyperlipidemia, serum triglyceride, total cholesterol, high density lipoprotein (HDL)-cholesterol, HDL2-cholesterol, HDL3-cholesterol, and apolipoprotein A-I (apo A-I) levels did not change during ω-3 FO supplementation for 8 weeks. The mean serum apo B concentration increased significantly [baseline, 2.56 ± 0.11 (± SEM) mmol/L; 4 weeks, 2.82 ± 0.13 mmol/L; 8 weeks, 2.80 ± 0.13 mmol/L; P < 0.01]. The mean plasma postheparin lipoprotein lipase activity increased transiently during the fourth week (baseline, 168 ± 17 U/mL; 4 weeks, 182 ± 18 U/mL; P < 0.05), whereas postheparin hepatic triglyceride lipase activity did not change. Glycemic control worsened transiently during the fourth week, (baseline, 7.7 ± 0.4%; 4 weeks, 8.4 ± 0.3%; P < 0.05). Both systolic and diastolic BP decreased significantly throughout the study (systolic BP: baseline, 142 ± 5 mm Hg; 8 weeks, 128 ± 5 mm Hg; diastolic BP: baseline, 88 ± 4 mm Hg; 8 weeks, 80 ± 3 mm Hg; P < 0.01). These findings suggest that in type II diabetics without overt hyperlipidemia, ω-3 FO supplementation does not improve either the glycemic control or serum lipids, and it is associated with a potentially detrimental rise in serum apo B concentrations. Until more information is available, use of such supplementation should be discouraged.

UR - http://www.scopus.com/inward/record.url?scp=0023740855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023740855&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 1

EP - 5

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -